Associated Genetic Biomarkers
AT rich interactive domain 1B (SWI 1-like) (ARID1B) is a gene that encodes a protein that is a component of the SWI/SNF chromatin remodeling complex. The protein functions in cell-cycle activation. Missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions and insertions are observed in cancers such as endometrial cancer, skin cancer, and stomach cancer.
ARID1B is altered in 4.79% of all cancers with lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in ARID1B are ARID1B Mutation (3.93%), ARID1B Loss (0.19%), ARID1B Amplification (0.10%), ARID1B G319dup (0.17%), and ARID1B A350dup (0.17%) .
ARID1B status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain ARID1B status as an inclusion criterion, 2 are phase 2 (2 open).
Trials with ARID1B status in the inclusion eligibility criteria most commonly target melanoma .
The most frequent alterations to serve as inclusion eligibility criteria are ARID1B Loss and ARID1B Mutation .
Niraparib, olaparib, and pembrolizumab are the most frequent therapies in trials with ARID1B as an inclusion criteria .
Significance of ARID1B in Diseases
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.